Jefferies Global Healthcare Conference
Logotype for Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Viridian Therapeutics Inc

Jefferies Global Healthcare Conference summary

16 Nov, 2026

LUMVOA launch

  • First-quarter launch revenue was $24.7 million, with >100 patients on therapy as of Sept. 30; management said execution exceeded expectations.

  • Most patients had a proptosis response after one infusion; chronic TED patients showed complete diplopia resolution, and the planned course is five infusions vs. TEPEZZA’s eight.

  • Management expects a fast path to peak in a new-start market, but said the actual timeline remains to be seen; launch is still early.

Commercial access and execution

  • Formal policy coverage reached 30% of covered lives by the end of September; other patients can pursue access through medical exceptions.

  • Payers indicated parity pricing could support parity coverage; TEPEZZA reached 85% of covered lives in nearly five years, while management targets critical mass within 6–9 months of launch.

  • More than 95% of ~2,000 core prescribers had been engaged within four weeks of launch; the field team was active with physicians within 24 hours of launch.

  • A permanent J-code takes effect Jan. 1; management expects limited overall impact, with potential help for smaller infusion centers.

SubQ elegrobart

  • After two positive Phase III readouts earlier in 2026, the BLA for subQ IGF-1R is planned for Q1 2027.

  • Development plans include Q4-weekly and Q8-weekly regimens; the Q8-weekly course would involve three administrations at day 1, week 8 and week 16.

  • Management expects subQ convenience to expand the market, particularly by reaching patients deterred by infusions; IV is expected to remain an option for controlled settings and severe, sight-threatening disease.

  • Q4-weekly data showed diplopia response and resolution; Q8-weekly dosing may suit patients whose primary concerns are proptosis or pain.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Viridian Therapeutics